

Lactobacillus reuteri normalizes altered fear memory in male *Cntnap4* knockout mice

Wenlong Zhang,^{a,c} Jie Huang,^{b,c} Feng Gao,^{b,c} Qianglong You,^{b,c} Liuyan Ding,^a Junwei Gong,^b Mengran Zhang,^b Runfang Ma,^b Shaohui Zheng,^b Xiangdong Sun,^b and Yunlong Zhang^{b,*}

^aDepartment of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China

^bDepartment of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China



Summary

Background Autism spectrum disorder (ASD) is a common neurodevelopmental disease, characterized by deficits in social communication, restricted and repetitive behaviours, and impaired fear memory processing. Severe gastrointestinal dysfunction and altered gut microbiome have been reported in ASD patients and animal models. Contactin associated protein-like 4 (*CNTNAP4*) has been suggested to be a novel risk gene, though its role in ASD remains unelucidated.

Methods *Cntnap4*^{-/-} mice were generated to explore its role in ASD-related behavioural abnormalities. Electrophysiological recording was employed to examine GABAergic transmission in the basolateral amygdala (BLA) and prefrontal cortex. RNA-sequencing was performed to assess underlying mechanisms. 16S rDNA analysis was performed to explore changes in faecal microbial composition. Male *Cntnap4*^{-/-} mice were fed with *Lactobacillus reuteri* (*L. reuteri*) or faecal microbiota to evaluate the effects of microbiota supplementation on the impaired fear conditioning mediated by *Cntnap4* deficiency.

Findings Male *Cntnap4*^{-/-} mice manifested deficiency in social behaviours and tone-cue fear conditioning. Notably, reduced GABAergic transmission and GABA receptor expression were found in the BLA but not the prefrontal cortex. In addition, gut *Lactobacillus* were less abundant in male *Cntnap4*^{-/-} mice, and *L. reuteri* treatment or faecal microbiota transplantation rescued abnormal tone-cued fear memory and improved local GABAergic transmission in the BLA of male *Cntnap4*^{-/-} mice.

Interpretation *Cntnap4* shapes GABAergic transmission of amygdala and fear conditioning, and microbial intervention represents a promising therapy in ASD intervention.

Funding National Natural Science Foundation of China, Science and Technology Planning Project of Guangzhou, Guangzhou Medical University, and China Postdoctoral Science Foundation.

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Keywords: Autism spectrum disorder; *Cntnap4*; Fear memory; GABAergic transmission; Gut microbiome

Introduction

ASD is a complex neurodevelopmental disease encompassing autistic disorder, Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder not otherwise specified, according to the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) definition.¹ The key diagnostic features of ASD patients include deficits in social communication and restricted, repetitive patterns of behaviour,

interest, or activities.¹⁻⁴ Several brain regions, such as the cerebral cortex, cerebellum, amygdala and hippocampus, underlie ASD.⁵⁻⁷ Among them, the amygdala is structurally and functionally linked with ASD, as evidenced by its reduced volume in autism patients and functional association with autism-related social behaviours.⁸⁻¹⁰ Because the amygdala is also important in fear memory processing,^{11,12} it may regulate fear conditioning in ASD. Abnormal fear memory alterations have been

*Corresponding author.

E-mail address: ylzhang@gzhmu.edu.cn (Y. Zhang).

^cThese authors contributed equally to this work.

Research in context

Evidence before this study

Accumulating evidence points to the importance of the gut microbiome in modulating social behaviours in ASD. *CNTNAP4* was identified as a novel risk gene for ASD. We previously demonstrated that *Cntnap4* deficiency contributes to the pathogenesis of neurodegenerative diseases. However, the molecular mechanism of *Cntnap4* deficiency and the role of gut microbiome dysbiosis in ASD-related behavioural abnormalities due to *Cntnap4* deficiency remain undefined.

Added value of this study

Our findings delineate effects of *Cntnap4* deficiency on social behaviours and tone-cue fear conditioning. Reduced GABAergic transmission in the basolateral amygdala (BLA) and decreased abundance of gut *Lactobacillus* were observed in male *Cntnap4*^{-/-} mice. Remarkably, *Lactobacillus reuteri* administration or faecal microbiota transplantation rescued

abnormal tone-cued fear memory and improved GABAergic transmission in the BLA of male *Cntnap4*^{-/-} mice. These observations underscore the mediatory roles of the microbiota in linking *CNTNAP4* genetic deficiency and impaired social behaviours in ASD.

Implications of all the available evidence

Our findings indicate a critical role for *Cntnap4* in shaping GABAergic transmission of the amygdala and fear conditioning. Additionally, as an emerging therapeutic tool to improve the behavioural abnormalities in ASD, microbial intervention represents a promising candidate therapy. Considering the growing prevalence of ASD and lack of efficient therapeutic interventions, our findings have important potential clinical applications in improving impaired social behaviours in ASD.

investigated in genetic and drug-induced autism models.^{13–16} However, the underlying mechanisms of fear memory alteration in ASD remain unclear.

More than 80% of ASD has high heritability,¹⁷ and several risk genes, such as *NLGN3*, *MECP2*, *SHANK2*, *SHANK3*, *ARID1B*, *CHD8*, and *ASH1L*, have been demonstrated to be genetically linked with ASD.^{18–25} Among these, contactin-associated protein-like 2 (*CNTNAP2*) and *CNTNAP4* are susceptible genes, and mutation or deletion of these genes lead to autism-like phenotypes.^{26–28} As a transmembrane protein member of the neuixin superfamily, *Cntnap4* is involved in neuron–glia interaction and is critical for neurological development and synaptic function.^{29,30} Utilizing its postsynaptic density-95, disks-large, and zonula occludens-1 (PDZ)-containing domain, *Cntnap4* interacts with Mint1, calcium/calmodulin-dependent serine protein kinase (CASK), and ligand of Numb-protein X2 (LN2) to regulate GABAergic (γ -aminobutyric acid producing) transmission and neuronal differentiation.^{31–33} In the brain, *Cntnap4* is mainly expressed in interneurons in the olfactory bulb, hippocampus and amygdala, and dopaminergic neurons in the substantia nigra.³⁰ Absence of *Cntnap4* has been observed to induce autism-related behavioural abnormality such as over-grooming by disturbing GABAergic signalling.²⁸ Recently, rare copy number variations (CNV) of *CNTNAP4* and noncoding variants within promoter of *CNTNAP4* have been reported to be associated with ASD.^{34,35} Furthermore, we and other groups demonstrated that deletion of *Cntnap4* or CNV polymorphisms of *CNTNAP4* cause neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), and neurological disorders, such as epilepsy.^{36–38} Because GABAergic signalling in the

amygdala is closely associated with the consolidation and extinction of fear memory,³⁹ we speculated that *Cntnap4* may also play a role in fear memory processing.

In addition to genetic associations, gene–environment interactions also contribute significantly to ASD pathogenesis.^{40,41} Notably, the gut microbiota is a critical player in gene–environment interactions for various human diseases.^{42,43} Previously, altered gut microorganisms and serious gastrointestinal problems have been reported in ASD patients,^{44,45} and transplantation of gut microbiota from human ASD patients has been shown to mediate autism-like abnormal behaviour and neuronal activity in germ-free mice.⁴⁶ Furthermore, microbiota transfer therapy shows benefits in treating ASD.⁴⁷ Intriguingly, lessons from *Cntnap2* knockout mice show segregated contributions of host genetics and the microbiome to autism-related social behaviour.⁴⁸ Nevertheless, the role of the gut microbiota in fear memory processing in ASD has not been fully elucidated.

In the present study, we investigated the contribution of the gut microbiota in altered fear memory processing in *Cntnap4*^{-/-} mice. We report for that male *Cntnap4*^{-/-} mice manifest deficiency in social behaviours and tone-cue fear conditioning. In addition, we found reduced GABAergic transmission in the basolateral amygdala (BLA) and decreased abundance of gut *Lactobacillus* in male *Cntnap4* deficiency mice. Supplementation of *Lactobacillus reuteri* (*L. reuteri*) or faecal microbiota transplantation (FMT) restored tone-cued fear memory and GABAergic plasticity in the amygdala of male *Cntnap4*^{-/-} mice. Together, these findings suggest that *Cntnap4* shapes GABAergic transmission in the amygdala and fear conditioning, for which the gut

microbiota provides a promising candidate for ASD intervention.

Methods

L. reuteri culture and treatment

L. reuteri (ATCC-PTA-6475, Guangdong Microbial Culture Collection Center, Guangzhou, China) was cultured anaerobically in de Man, Rogosa, and Sharpe (MRS) broth at 37 °C as previously described.⁴⁸ Briefly, cultures were centrifuged, washed, resuspended in PBS, and frozen at -80 °C until use. Mice were intragastrically administered live *L. reuteri* (1 × 10⁸ organisms/mouse/day) for 4 weeks.

Faecal microbiota transplantation

Fresh faeces were collected and transplanted to male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice according to a previous study.⁴⁹ Briefly, fresh stools were collected from healthy male wild-type C57BL/6J mice, and 100 mg of faeces were immediately placed into 1 mL of sterile 0.01 M PBS and steeped for 1 min. Then, the dissolved faeces were centrifuged at 900 g at 4 °C for 3 min. The suspension was collected, and bacterial suspension was then delivered to each recipient mouse (10 mL/kg) via oral gavage for seven consecutive days.

Animals

Cntnap4^{-/-} mice were generated by Shanghai Model Organisms Center, Inc (Shanghai, China) according to our previous report.³⁶ First, the mMMESSAGE mMA-CHINE T7 Ultra Kit (Ambion, TX, USA) was used to transcribe Cas9 mRNA, and the MEGAshortscript Kit (ThermoFisher, Waltham, MA, USA) was used to transcribe four single guide RNAs (sgRNAs) targeted to delete exon 3 of *Cntnap4* gene (sgRNA1: TGCCACTTGTGTTTCATTTA GAGG; sgRNA2: TGCCTCTAAAT GAA CACAA GTGG; sgRNA3: ATGGTTTAGT GGACTCGTGTGGG; sgRNA4: CATGGTTTGTGGACTCGTGTGG) *in vitro*. Then the Cas9 mRNA and sgRNAs were injected into zygotes of C57BL/6J mice and transferred to pseudopregnant recipients. The *Cntnap4*^{-/-} mice were validated by PCR and sequencing using primer pairs: F-5'-CCAAACCAATT-CATTCTT-3'; R-5'-GCAACACTGTAAATCAGC CATA-3'. Male and female *Cntnap4*^{-/-} mice (nearly 12–14 weeks) were double-blindly and randomly used in this study, and age- and sex-matched *Cntnap4*^{+/+} littermates were set as the control. Four mice were kept in each cage under a controlled 12/12-h light/dark cycle, temperature (22 ± 1 °C), relative humidity (60 ± 5%), and food and water were provided *ad libitum*. The total number of animals we used was 171 mice; there were 125 male mice (62 *Cntnap4*^{+/+} mice and 63 *Cntnap4*^{-/-} mice) and 46 female mice (25 *Cntnap4*^{+/+} mice and 21 *Cntnap4*^{-/-} mice). We calculate the samples size based on experience

with the respective tests, variability of the assays, and interindividual differences within groups.

Behavioural tests

Open field test (OFT)

The OFT was performed according to our previous study.⁵⁰ Before the OFT, mice were habituated in the testing room for 1 day. The open field consisted of a box (40 cm × 40 cm × 40 cm) including peripheral and central sectors. Each mouse was placed individually in the central sector, and its locomotion was recorded with the EthoVision XT tracking system (Beijing, China). Behavioural parameters recorded during the 15 min test period included the total distance travelled and the time spent in the central and the peripheral zone. After each trial, the apparatus was cleaned with 75% ethanol.

Social interaction test (SIT)

The SIT was performed as previously described.⁵¹ First, the mice were placed in an empty Plexiglas arena consisting of corner zones and an interaction zone for 150 s. The interaction zone of the test arena encompasses a 14 cm × 24 cm rectangular area projecting 8 cm around the wire-mesh enclosure. The corner zones encompass a 9 cm × 9 cm area projecting from two corner joints opposing the wire-mesh enclosure. Next, a CD-1 mouse was placed within the wire-mesh enclosure base and the test mouse was placed back in the test arena for 150 s. The total distance travelled and time spent in the corner or interacting zone with the CD-1 mouse were recorded via EthoVision XT (Beijing, China).

Social partition test

The test was performed as previously described, with a few modifications.⁵² Each test mouse was removed from the homecage and housed individually in a new cage, which was equally separated by a perforated transparent partition (0.6 cm-diameter holes) for 3 days before the test. On the test day 1, each test mouse was housed overnight with an age- and gender-matched C57BL/6J mouse (familiar partner) placed on the other side of the partition. On the test day 2, the first 5 min activity at the partition board with the familiar partner was recorded; then the familiar partner was replaced by a novel age- and gender-matched C57BL/6J mouse (novel partner), and a 5-min interest at the partition was recorded; the novel partner was substituted by the original familiar partner, and the last 5 min activity at the partition was recorded. The time spent at the partition in each 5 min trial for the test mouse was assayed using Observer XT (EthoVision XT, Beijing, China) by a double-blind experimenter.

Three-chamber test

A three-chambered apparatus was used to assess the social behaviours as previously described, with a few

modifications.⁵³ After a 10 min habituation period in the middle chamber, each test mouse was allowed to explore all 3 empty chambers for 10 min (Phase 1). Then an age- and gender-matched C57BL/6J mouse (unfamiliar stranger 1) was placed into a wire cage, and an identical empty wire cage was placed in the opposite chamber. The test mouse was then immediately placed in the middle chamber with the 2 doorways open, a 10 min sociability test was performed and the mouse was allowed to freely explore all chambers (Phase 2). In the last session, the empty wire cage was substituted with one that another age- and gender-matched C57BL/6J mouse (unfamiliar stranger 2) was placed in, and, as described in Phase 2, a 10 min social novelty preference test was recorded (Phase 3). The time spent in each chamber was calculated and analysed using Observer XT (EthoVision XT, Beijing, China) by a double-blind experimenter.

Fear conditioning test

A fear conditioning test was performed according to our previous work.¹² The fear conditioning test was performed using the NIR Video Fear Conditioning Package for Mice (Med Associates, Vermont, USA). On day 1, after a 180 s habituation, the mice were exposed to a tone (75 dB, 2800 Hz, 30 s) and then to the same tone combined with electrical shock (1 mA) for 1 s, which was repeated four times at an interval of 110 s. On day 2, the mice were placed in the same chamber as on day 1 for 5 min without tone or electrical shock to assess context-dependent fear conditioning. On day 3, the mice were placed in a black-coloured chamber of the same size to assess the baseline activity for 3 min, and then the same tone as on day 1 was applied for 3 min to assess tone-dependent fear conditioning. For evaluation of context- and tone-dependent conditioning, the freezing scores were obtained by the Video Freeze® Software system (Med Associates, Vermont, USA) and expressed as percent of the baseline activity.

Y maze test

A Y maze test was performed as we described previously.⁵⁴ The Y maze consisted of three arms (30 cm long, 10 cm wide, and 20 cm high) and a connected central area. Mice were placed within the centre zoom and were allowed to explore in the Y maze freely for 8 min. A video tracking system (EthoVision XT; Beijing, China) was used to analyse spontaneous alterations.

Elevated plus maze (EPM)

The EPM was performed according to our previous study.⁵⁵ The EPM device consists of two open arms (30 × 5 cm), two closed arms (30 × 5 × 15 cm), and a central zone (5 × 5 cm). The device was elevated to a height of 50 cm above the ground. Mice were placed in the central intersection for 5 min. A video tracking system (EthoVision XT) was used to record the time spent in the open and closed arms.

Tail suspension test (TST)

The TST was performed as we previously described.⁵⁶ Mice were suspended 5 cm above the ground using an adhesive tape placed approximately 1 cm from the tip of the tail. The immobility time was recorded via EthoVision XT for 6 min.

RNA-sequencing (RNA-seq)

RNA-seq was performed according to our recent work.⁵⁰ Total RNA from the amygdala of male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice was collected using Trizol (Invitrogen, Carlsbad, CA, USA). Library preparation for RNA-seq was performed using the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA) with 300 ng of total RNA. Single read (45 bp) sequencing was conducted using the HiSeq 2500 platform (Illumina, San Diego, CA). Reads were aligned with STAR (v2.5.3a) against the murine reference genome by Novogene (Beijing, China). Transcripts were analysed with the Partek E/M algorithm and processed for normalization with the DESeq2 algorithm. Differentially expressed genes (DEGs) were set on batch effect (fold-change |1.5|, FDR-adjusted *p* value < 0.05). Samples were subjected to differential expression analysis with DESeq2 (v1.14.1). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes (DEGs) and gene ontology (GO) term enrichment analysis were performed using the R package (v 3.5.1). RNA-seq data used in this study are available under GEO: GSE208542 for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice and GSE208397 for female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice.

Quantitative real-time (RT)-PCR

Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). Afterward, RNA was transcriptionally reversed to cDNA using a Reverse Transcription Kit (QIAGEN, Waltham, MA, USA), and relative gene expressions were calculated using SYBR Green PCR Mix (Takara). Results were obtained by using the $2^{-\Delta\Delta CT}$ method as we described previously.⁵⁰ Primers used in this study are listed in [Supplementary Table S1](#). Primers for *L. reuteri* and general bacteria were reported by Sgritta et al.⁵⁷ GAPDH mRNA was used to normalize the levels of GABA receptors and oestrogen receptors in the amygdala, while general bacteria mRNA was used to normalize the level of *L. reuteri* in the colon.

16S rDNA analysis of faecal samples

Total genome DNA from faecal samples was extracted using the CTAB/SDS method.⁵⁴ The DNA concentration and purity were examined by 1% agarose gels, and the DNA was diluted to 1 ng/μL using sterile water. 16S/18S rRNA genes were amplified using specific primers (16S V4: 515F-806R; 18S V4: 528F-706R; 18S V9: 1380F-

1510R; ITS1: ITS5-1737F, ITS2-2043R; ITS2: ITS3-2024F, ITS4-2409R) with barcodes. All PCR reactions were carried out in 30 μ L reactions with 15 μ L of High-Fidelity PCR Master Mix (New England Biolabs [NEB], Ipswich, MA, USA), 0.2 μ M forward and reverse primers, and 10 ng template DNA. Thermal cycling consisted of initial denaturation at 98 °C for 1 min, followed by 30 cycles of denaturation at 98 °C for 10 s, annealing at 50 °C for 30 s, elongation at 72 °C for 30 s, and a final elongation step at 72 °C for 5 min. Samples with bright main strips between 400 and 450 bp were chosen for further PCR quantification and qualification. Sequencing libraries were generated using the Ultra™ DNA Library Prep Kit for Illumina (NEB, Ipswich, MA, USA) according to the manufacturer's recommendations. The library quality was assessed on the Qubit2.0 Fluorometer (ThermoFisher, Waltham, MA, USA) and Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA). Finally, the library was sequenced on an Illumina HiSeq platform (Illumina, San Diego, CA), and 250 bp paired-end reads were generated.

Microbial analysis

Paired-end reads from the original DNA fragments were merged by using FLASH.⁵⁸ Sequences were analysed using the Quantitative Insights Into Microbial Ecology (QIIME) software package,⁵⁹ and in-house Perl scripts were used to analyse α - (within samples) and β - (among samples) diversity. Sequences with $\geq 97\%$ similarity were assigned to the same operational taxonomic units (OTUs).⁶⁰ QIIME calculates both weighted and unweighted unifracs for Principal Coordinate Analysis (PCoA) and Unweighted Pair Group Method with Arithmetic mean (UPGMA) clustering. To further explore the data of microbial diversity of the differences among the samples, significance tests were conducted with statistical analysis methods, including T-test, MetaStat, LEfSe, Anosim and MRPP.

Whole-cell electrophysiological recording

Electrophysiological recording was performed as previously reported.^{55,61} Briefly, mice were anesthetized with isoflurane. Brains were rapidly removed and chilled in ice-cold modified artificial cerebrospinal fluid (ACSF) containing (in mM): 120 Choline-Cl, 2.5 KCl, 7 MgCl₂, 0.5 CaCl₂, 1.25 NaH₂PO₄, 25 NaHCO₃, and 10 Glucose. Coronal BLA and prefrontal cortical (PrL) slices of 300 μ m thickness were generated in ice-cold modified ACSF using a vibratome (Leica VT-1000S, Germany) and transferred to normal ACSF containing (in mM): 126 NaCl, 3 KCl, 1 MgSO₄, 2 CaCl₂, 1.25 NaH₂PO₄, 26 NaHCO₃, and 10 Glucose. The brain slices were incubated at 32 °C for 30 min and at room temperature for an additional 1 h before recording. All liquids were saturated with 95% O₂/5% CO₂ (vol/vol).

Brain slices were then transferred to a recording chamber, and the ACSF was continuously overlaid at a flow rate of 2 mL/min. To record the spontaneous inhibitory postsynaptic current (sIPSC), PrL 2–3 layer and BLA pyramidal neurons were held at -70 mV in the presence of 20 μ M CNQX and 100 μ M AP-5. The pipette solution contained (in mM): 140 CsCl, 10 Hepes, 0.2 EGTA, 1 MgCl₂, 4 Mg-ATP, 0.3 Na-GTP, 10 phosphocreatine and 5 QX314 (pH 7.4, 285 mOsm). Miniature events were analysed with the MiniAnalysis program (Synaptosoft Inc., NJ, USA). For spontaneous excitatory postsynaptic current (sEPSC) recording, the PrL 2–3 layer and BLA pyramidal neurons were held at -70 mV in the presence of 20 μ M RS-95531. The pipette solution contained (in mM): 125 Cs-methanesulfonate, 5 CsCl, 10 Hepes, 0.2 EGTA, 1 MgCl₂, 4 Mg-ATP, 0.3 Na-GTP, 10 phosphocreatine and 5 QX314 (pH 7.4, 285 mOsm).

In all experiments, the series resistance was maintained below 20 M Ω and not compensated. The cells were eliminated if series resistance fluctuated more than 20% of initial values. Data were acquired with a MultiClamp 700B amplifier and 1440A digitizer (Molecular Devices, San Jose, CA, USA), which were filtered at 1 kHz and sampled at 10 kHz.

Immunofluorescence

Mouse brains were fixed in 4% paraformaldehyde and sectioned with a freezing microtome (Leica, Hamburg, Germany). The sections were blocked with 5% bovine serum albumin and then incubated overnight at 4 °C with the primary antibodies, c-Fos (Cat# sc-271243; Research Resource Identifiers [RRID]: AB_10610067, Santa Cruz Biotechnology, Dallas, TX, USA), and parvalbumin (PV, #235; RRID not available, Swant Inc., Rte Ancienne Papeterie Marly Innovation Center, Marly, Switzerland). The appropriate species of Alexa Fluor 488/594-conjugated secondary antibodies, goat anti-mouse IgG (H + L) (Cat# 70-GAM4882; RRID not available, Multi Sciences, Hangzhou, China) and goat anti-rabbit IgG (H + L) (Cat# 70-GAR5942; RRID not available, Multi Sciences, Hangzhou, China), were then applied to the sections. Images were obtained on a confocal Leica microscope (SP8; Leica, Hamburg, Germany). Image analysis was performed by ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Western blotting

The amygdala tissues were collected, and the proteins were extracted using RIPA Lysis Buffer containing protease inhibitors (Beyotime Biotechnology, Shanghai, China). The protein samples were separated on 4–20% Tris-glycine and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% bovine serum albumin and incubated with different primary antibodies, Cntnap4 (Cat# orb544737; RRID not available, Biorbyt LLC, San Francisco, CA, USA),

GABA_Aα1 (Cat# 06-868; RRID: [AB_310272](#), Millipore, Billerica, MA, USA), GABA_Aα2 (Cat# ab193311; RRID: [AB_2890213](#), Abcam, Cambridge, MA, USA), GABA_Aα5 (Cat# sc-393921; RRID not available, Santa Cruz Biotechnology, Dallas, TX, USA), GABA_Aβ3 (Cat# sc-376252; RRID: [AB_11012142](#), Santa Cruz Biotechnology, Dallas, TX, USA), GABA_BR1 (Cat# sc-166408; RRID: [AB_2108175](#), Santa Cruz Biotechnology, Dallas, TX, USA), GAPDH (Cat# 60004-1; RRID: [AB_2107436](#), Proteintech Group, Rosemont, IL, USA). After incubation with horseradish peroxidase (HRP)-labelled secondary antibodies, goat anti-rabbit IgG (Cat# A0208; RRID: [AB_2892644](#), Beyotime Biotechnology, Shanghai, China) and goat anti-mouse IgG (Cat# A0216; RRID: [AB_2860575](#), Beyotime Biotechnology, Shanghai, China), images were taken on the GeneGnome XRQ Chemiluminescence imaging system (Gene Company, Hong Kong, China). Protein levels were normalized against GAPDH. Quantification was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data are presented as mean ± standard error of the mean (SEM). In this study, we performed the Shapiro–Wilk test to evaluate the normality of parameters. The parameters with $p > 0.05$ were considered according to the normal distribution and reaching the condition of parametric methods. Sample sizes were chosen based on the means and variation of preliminary data to achieve at least 80% power and allow for a 5% type I error. All calculations for sample sizes were done using an online sample size calculator (<https://clincalc.com/stats/samplesize.aspx>). Data were analysed using one-way and two-way ANOVA followed by the Tukey's multiple comparisons test or Student's *t*-test, as appropriate. Differences with a p -value < 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software, La Jolla, CA, USA). P -values are represented as * $p < 0.05$ and ** $p < 0.01$.

Ethics statement

All animal experimental procedures were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University (Approval number: GY2020-041) and National Institute of Health guidelines on the care and use of animals (NIH Publications No. 8023, revised 1978).

Role of funders

The funders had no role in study design, data collection, data analysis, interpretation, writing of the manuscript, or decision to submit the paper for publication.

Results

Male *Cntnap4* deficient mice show impaired social behaviour and tone-cued fear conditioning

We utilized the *Cntnap4*^{-/-} mice previously generated by our lab³⁶ to detect its mechanism in promoting autism-like behaviours. Both male and female *Cntnap4*^{-/-} mice displayed face and body hair loss and lesions due to over-grooming (Fig. 1a), which is consistent with previous report.²⁸ Male *Cntnap4*^{-/-} mice travelled less distance in the open field as compared with *Cntnap4*^{+/+} mice (Fig. 1b and Supplementary Fig. S1a, $p = 0.0036$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.5867$ for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice), while the number of entries and duration in the centre zone showed no obvious differences between *Cntnap4*^{-/-} and *Cntnap4*^{+/+} mice (Supplementary Fig. S1b and c). In addition, male but not female *Cntnap4*^{-/-} mice manifested impaired social interaction, which is a core symptom of ASD that was indicated experimentally by a reduced social interaction ratio, an increased ratio in the corner, and reduced time in the interaction zone (Fig. 1c and d, $p = 0.0197$ and 0.0394 for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.9536$ and 0.9997 for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice, respectively; Fig. 1e, $p = 0.8101$ and $p = 0.0433$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice in no target and target conditions). We further performed a social partition test to assess social interaction and recognition in mice. In the social partition test, female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice and male *Cntnap4*^{+/+} mice exhibited a significant increase in time spent with novel mice at the perforated partition, in contrast to the time spent with familiar mice (Fig. 1f, male *Cntnap4*^{+/+} mice: $p = 0.0138$ and 0.0187 for facing novel mice vs. familiar mice and original familiar mice vs. novel mice; female *Cntnap4*^{+/+} mice: $p = 0.0015$ and 0.0024 for facing novel mice vs. familiar mice and original familiar mice vs. novel mice; female *Cntnap4*^{-/-} mice: $p = 0.0030$ and 0.0096 for facing novel mice vs. familiar mice and original familiar mice vs. novel mice). While male *Cntnap4*^{-/-} mice did not show differential interest in familiar and novel mice, based on the time spent at the perforated partition (Fig. 1f, male *Cntnap4*^{-/-} mice: $p = 0.0260$ and 0.9850 for facing novel mice vs. familiar mice and original familiar mice vs. novel mice). We also utilized the three-chamber test to assess the social approach. During the first 10-min trial (phase 1), all group mice spent similar time habituating and exploring bilateral chambers, which indicated a lack of side preference in the experimental environment (Fig. 1g). Then mice were subjected to a test of sociability. During phase 2, both male and female *Cntnap4*^{-/-} mice did not show a significant difference from *Cntnap4*^{+/+} mice in the time spent with an inanimate object (Fig. 1h, $p < 0.0001$ for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice, $p < 0.0001$ and $p = 0.0009$ for female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice; j and k, $p = 0.8970$

and 0.9972 for male and female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). During phase 3, once a novel social partner was placed in the empty wire cage, the male *Cntnap4*^{-/-} mice still spent a similar length of time in the two chambers (Fig. 1i, $p = 0.0004$ and $p = 0.9885$ for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice) and showed less preference for the novel mouse over the familiar mouse than the male *Cntnap4*^{+/+} mice (Fig. 1l, $p = 0.0445$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). Furthermore, the female *Cntnap4*^{-/-} mice were more likely to interact with novel stranger mice compared with the *Cntnap4*^{+/+} mice (Fig. 1i, $p = 0.0008$ and $p = 0.0004$ for female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice; 1l, $p > 0.9999$ for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). To determine if *Cntnap4* deletion regulates the function of the amygdala, we examined tone-cued fear conditioning in *Cntnap4*^{-/-} mice. The mice were subjected to 4 pairs of tone and foot shock during the training day, and the freezing levels in a new environment in a probe test were examined (Fig. 1m). Both male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice showed unchanged freezing levels in the contextual test and before the tone was applied (Fig. 1n and o). However, the freezing time was decreased in male *Cntnap4*^{-/-} mice as compared with *Cntnap4*^{+/+} mice in the presence of a tone, suggesting that tone-cued fear conditioning was impaired in male *Cntnap4*^{-/-} mice (Fig. 1p, $p = 0.0134$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.6434$ for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). Moreover, spontaneous alterations in the Y maze test were impaired in female *Cntnap4*^{-/-} mice, suggesting that the working memory may have been disturbed (Supplementary Fig. S1d, $p = 0.9742$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.0226$ for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). Both *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice showed no obvious changes in the elevated plus maze and tail suspension test (Supplementary Fig. S1e and f). These observations indicate that social behaviour and tone-cued fear conditioning are impaired in male *Cntnap4* deficient mice.

Cntnap4 is critical for GABAergic transmission in the amygdala

Because the BLA-prefrontal cortex (PFC) circuitry plays a distinct role in regulating fear memory processing,^{62,63} we investigated the effect of *Cntnap4* deficiency on synaptic transmission in the BLA and PFC. The sIPSC amplitude in the BLA was decreased in male *Cntnap4*^{-/-} compared with *Cntnap4*^{+/+} mice (Fig. 2a and b, $p = 0.0065$ for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.9203$ for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice). On the other hand, the sIPSC frequency in the BLA and the sIPSC amplitude and frequency in the prefrontal cortical PrL showed no obvious changes in male and female *Cntnap4*^{-/-} mice (Fig. 2c–f). Additionally, the sEPSC frequency in the

BLA was reduced in female *Cntnap4*^{-/-} compared with *Cntnap4*^{+/+} mice, while the sEPSC amplitude in the BLA and sEPSC amplitude and frequency in the PrL were unaltered in male and female *Cntnap4*^{-/-} mice (Supplementary Fig. S2a–f, $p = 0.3595$, 0.5052 , 0.0978 , and 0.0954 for male *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice; $p = 0.2862$, 0.0001 , 0.9745 , and 0.4567 for female *Cntnap4*^{+/+} mice vs. *Cntnap4*^{-/-} mice in Fig. 2b, c, e, and f, respectively). These results suggest that *Cntnap4* deficiency may affect amygdaloid GABAergic transmission in male mice.

Given that male *Cntnap4*^{-/-} mice display an impaired fear conditioning phenotype, we further explored the effects of *Cntnap4* deficiency on amygdaloid gene expression pathways by RNA-sequencing. PCA score plots revealed a distinct separation of components in the male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} groups (Fig. 3a). The gene expression distribution and FPKM density distribution appeared largely similar (Fig. 3b and Supplementary Fig. S3). However, volcano plots revealed 552 DEGs (334 increased and 218 decreased) between male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice (Fig. 3c). The downregulated DEGs were enriched in GO and KEGG pathways related to GABAergic transmission, such as “GABAergic synapse”, “GABA receptor complex”, “GABA_A receptor complex”, “GABA receptor activity”, “GABA_A receptor activity” and “GABA-gated chloride ion channel activity” (Fig. 3d–f, Supplementary Fig. S4). Individual downregulated DEGs enriched in “GABAergic transmission and axon ensheathment” are shown in a heatmap (Fig. 3g). Specifically, *Cntnap4*, *Car2*, *Gabra1*, *Gabrb2*, *Gabrg1*, *Gabrg2* and *Kif5b* were downregulated DEGs related to GABAergic synaptic transmission in male *Cntnap4*^{-/-} mice. Likewise, GO and KEGG pathways enriched by upregulated DEGs are consistent with the electrophysiological recording data (Supplementary Figs. S5 and S6), thus further supporting the role for *Cntnap4* in GABAergic transmission.

To understand the mechanism behind the sex differences in the behaviours, we also studied the transcriptomic alteration in the female *Cntnap4*^{-/-} mice. PCA score plots showed a distinct separation of components in the *Cntnap4*^{+/+} and *Cntnap4*^{-/-} groups (Fig. 4a), and volcano plots revealed 2259 DEGs (1028 increased and 1231 decreased) between female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice (Fig. 4b). Like the RNA-seq data of male mice, the gene expression distribution and FPKM density distribution from female RNA-seq data also appeared largely similar (Supplementary Fig. S7a and b). However, unlike RNA-seq data from male mice, the upregulated DEGs in female *Cntnap4*^{-/-} mice versus *Cntnap4*^{+/+} mice were found to be enriched in “GABAergic synapse” in KEGG pathways (Fig. 4c). Here, we showed the upregulated DEGs enriched in “GABAergic synapse” and downregulated DEGs enriched in “Cellular hormone




Fig. 1: Male *Cntnap4*^{-/-} mice display deficits in social behaviours and tone-cued fear conditioning. (a) Face and body hair loss and lesions due to over-grooming in *Cntnap4*^{-/-} mice. (b) Total travelled distance in the open field test (OFT). $F_{1, 37} = 2.716$, $p = 0.1078$ for sex-genotype interaction; $F_{1, 37} = 0.1366$, $p = 0.7138$ for genotype; $F_{1, 37} = 12.14$, $p = 0.0013$ for sex. (c and d) Social interaction (SI) ratio in the interaction and corner zone for male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (c) $F_{1, 37} = 6.263$, $p = 0.0169$ for sex-genotype interaction; $F_{1, 37} = 0.2187$, $p = 0.6428$ for genotype; $F_{1, 37} = 3.063$, $p = 0.0884$ for sex. (d) $F_{1, 37} = 4.000$, $p = 0.0529$ for sex-genotype interaction; $F_{1, 37} = 2.426$, $p = 0.1279$ for genotype; $F_{1, 37} = 3.463$, $p = 0.0707$ for sex. (e) Time spent in the interaction zone for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice with or without a target. $F_{1, 37} = 1.728$, $p = 0.1966$ for sex-genotype interaction; $F_{1, 37} = 0.02267$, $p = 0.8811$ for genotype; $F_{1, 37} = 6.619$, $p = 0.0141$ for sex. (f) Social partition test of male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice facing familiar and novel mice. Male *Cntnap4*^{+/+} mice, $F_{2, 15} = 6.763$, $p = 0.0081$; male *Cntnap4*^{-/-} mice, $F_{2, 15} = 5.443$, $p = 0.0167$; female *Cntnap4*^{+/+} mice, $F_{2, 15} = 12.08$, $p = 0.0007$; female *Cntnap4*^{-/-} mice, $F_{2, 15} = 9.434$, $p = 0.0022$. (g-i) In the three-chambered social approach task, time spent in chambers during different 10-min trials. (g) Male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 0.003266$, $p = 0.9550$ for orientation-genotype interaction; $F_{1, 20} = 1.791$, $p = 0.1958$ for orientation; $F_{1, 20} = 0.08191$, $p = 0.7777$ for genotype; female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 0.01495$, $p = 0.9039$ for orientation-genotype interaction; $F_{1, 20} = 0.4539$, $p = 0.5082$ for orientation; $F_{1, 20} = 0.5047$, $p = 0.4856$ for genotype. (h) Male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 1.538$, $p = 0.2293$ for target-genotype interaction; $F_{1, 20} = 0.01927$, $p = 0.8910$ for target; $F_{1, 20} = 140.6$, $p < 0.0001$ for genotype; female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 0.6996$, $p = 0.4128$ for target-genotype interaction; $F_{1, 20} = 0.6795$, $p = 0.4195$ for target; $F_{1, 20} = 54.24$, $p < 0.0001$ for genotype. (i) Male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 10.80$, $p = 0.0037$ for target-genotype interaction; $F_{1, 20} = 0.07541$, $p = 0.7864$ for target; $F_{1, 20} = 13.97$, $p = 0.0013$ for genotype; female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice: $F_{1, 20} = 0.04257$, $p = 0.8386$ for target-genotype interaction; $F_{1, 20} = 0.1184$, $p = 0.7343$ for target; $F_{1, 20} = 46.70$, $p < 0.0001$ for genotype. (j) Trajectory diagram during the second 10-min trial. Male *Cntnap4*^{-/-} mice spent a similar length of time in the two chambers (k) and showed less preference for the novel mouse over the familiar mouse than the male *Cntnap4*^{+/+} mice (l). (k) $F_{1, 20} = 0.1251$, $p = 0.7273$ for sex-genotype interaction; $F_{1, 20} = 3.513$, $p = 0.0756$ for genotype; $F_{1, 20} = 0.3997$, $p = 0.5344$ for sex. (l) $F_{1, 20} = 4.260$, $p = 0.0522$ for sex-genotype interaction; $F_{1, 20} = 0.8843$, $p = 0.3583$ for genotype; $F_{1, 20} = 3.902$, $p = 0.0622$ for sex. (m) Schematic model of fear conditioning test. (n and o) Freezing levels of male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice in the contextual test and before the tone was




Fig. 2: The frequency of sIPSC in the BLA is decreased in male *Cntnap4*^{-/-} mice. (a and d) Representative traces of GABA receptor-mediated sIPSCs in the BLA and PrL. All sIPSCs were recorded at a holding potential of -70 mV. (b and e) Cumulative frequency plots (left) and quantitative analysis (right) of the amplitude of GABA receptor-mediated sIPSCs in the BLA and PrL. (b) $F_{1, 64} = 7.766$, $p = 0.0070$ for sex-genotype interaction; $F_{1, 64} = 49.67$, $p < 0.0001$ for genotype; $F_{1, 64} = 3.469$, $p = 0.0671$ for sex. (e) $F_{1, 64} = 2.716$, $p = 0.1042$ for sex-genotype interaction; $F_{1, 64} = 0.7950$, $p = 0.3759$ for genotype; $F_{1, 64} = 3.185$, $p = 0.0791$ for sex. (c and f) Cumulative frequency plots of the interevent interval (left) and quantitative analysis of the frequency of GABA receptor-mediated sIPSCs (right) in the BLA and PrL. (c) $F_{1, 64} = 0.6972$, $p = 0.4068$ for sex-genotype interaction; $F_{1, 64} = 14.81$, $p = 0.0003$ for genotype; $F_{1, 64} = 3.143$, $p = 0.0810$ for sex. (f) $F_{1, 64} = 0.3361$, $p = 0.5641$ for sex-genotype interaction; $F_{1, 64} = 8.825$, $p = 0.0042$ for genotype; $F_{1, 64} = 3.048$, $p = 0.0856$ for sex. Results are expressed as the mean \pm SEM. 16–18 slices from $n = 4$ mice per group. ** $p < 0.01$ vs. *Cntnap4*^{+/+} mice. Statistical significance was determined by two-way ANOVA + Bonferroni's multiple comparisons test.

metabolic process” in the heatmap (Fig. 4d). To identify the effects of sex differences on GABAergic transmission we observed, we evaluated the mRNA expression of the representative up- or downregulated DEGs from male and female RNA-seq data. We found that the mRNA expressions of *Car2*, *Gabra1*, *Gabrg1*, *Gabrg2*, *Gls2*, and *Gabbr2*, which are GABA receptors or related to GABA metabolism, were decreased in the amygdala of male *Cntnap4*^{-/-} mice (Fig. 4e, Student's *t* test, *Car2*: $t = 16.16$, $df = 4$, $p < 0.0001$; *Gabra1*: $t = 6.046$, $df = 4$, $p = 0.0038$; *Gabrg1*: $t = 13.00$, $df = 4$, $p = 0.0002$; *Gabrg2*: $t = 12.77$, $df = 4$, $p = 0.0002$; *Gls2*: $t = 12.84$, $df = 4$, $p = 0.0002$; *Gabbr2*: $t = 6.612$, $df = 4$, $p = 0.0027$). Consistent with the RNA-seq data, *Gabra1*, *Gabrb2*, *Gabrg1*, *Gabrg2*, *Kif5b*, *Slc38a2*, *Gls*, and *Gabbr2* expressions were increased in the amygdala of female *Cntnap4*^{-/-} mice (Fig. 4e, Student's *t* test, *Gabra1*: $t = 22.10$, $df = 4$, $p < 0.0001$; *Gabrb2*: $t = 5.779$, $df = 4$,

$p = 0.0045$; *Gabrg1*: $t = 16.39$, $df = 4$, $p < 0.0001$; *Gabrg2*: $t = 4.230$, $df = 4$, $p = 0.0134$; *Kif5b*: $t = 10.87$, $df = 4$, $p = 0.0004$; *Slc38a2*: $t = 12.68$, $df = 4$, $p = 0.0002$; *Gls*: $t = 3.568$, $df = 4$, $p = 0.0234$; *Gabbr2*: $t = 14.89$, $df = 4$, $p = 0.0001$). Furthermore, we found that several pathways enriched by downregulated DEGs were related to hormone metabolism (Fig. 4f). We then examined the hormone receptors, such as *Esr1* (encoding oestrogen receptor 1), *Esr2* (encoding oestrogen receptor 2), *Pgr* (encoding progesterone receptor), and *Ar* (encoding androgen receptor). Intriguingly, *Esr1* expression was increased and *Pgr* expression was decreased in the amygdala of male *Cntnap4*^{-/-} mice versus *Cntnap4*^{+/+} mice (Fig. 4g, Student's *t* test, *Esr1*: $t = 13.46$, $df = 4$, $p = 0.0002$; *Pgr*: $t = 11.86$, $df = 4$, $p = 0.0003$), while *Esr1* and *Esr2* expressions were decreased and *Pgr* expression was increased in the amygdala of female *Cntnap4*^{-/-} mice versus *Cntnap4*^{+/+} mice (Fig. 4g, Student's *t* test,

applied. (n) $F_{1, 37} = 0.00767$, $p = 0.9307$ for sex-genotype interaction; $F_{1, 37} = 0.1105$, $p = 0.7414$ for genotype; $F_{1, 37} = 5.808$, $p = 0.0210$ for sex. (o) $F_{1, 37} = 1.040$, $p = 0.3145$ for sex-genotype interaction; $F_{1, 37} = 7.847$, $p = 0.0080$ for genotype; $F_{1, 37} = 0.06895$, $p = 0.7943$ for sex. (p) Reduced freezing time in male *Cntnap4*^{-/-} mice upon tone-cued fear conditioning. $F_{1, 37} = 1.901$, $p = 0.1762$ for sex-genotype interaction; $F_{1, 37} = 2.687$, $p = 0.1096$ for genotype; $F_{1, 37} = 9.505$, $p = 0.0039$ for sex. Results are expressed as the mean \pm SEM. In b–e and m–p, $n = 11$, 10, 12, 8 for male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice, respectively; in f–l, $n = 6$ per group. ** $p < 0.01$, * $p < 0.05$. Statistical significance was determined by two-way ANOVA with Tukey's multiple comparisons test for b–e and g–p and one-way ANOVA with Tukey's multiple comparisons test for f.




Fig. 3: Transcriptome analysis of amygdala DEGs in male *Cntnap4*^{-/-} mice. (a) PCA score plots revealing a distinct separation of components in *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (b) Gene expression distribution of DEGs in *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (c) Volcano plot showing the DEGs between *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (d) GO pathways enriched by downregulated DEGs in *Cntnap4*^{-/-} mice compared with *Cntnap4*^{+/+} mice. GABAergic pathways are highlighted in red. (e and f) Representative GO and KEGG pathways enriched by downregulated DEGs. (g) Hierarchical clustering of 25 downregulated DEGs enriched in GABAergic synaptic transmission and axon ensheathment processes.

Esr1: $t = 16.27$, $df = 4$, $p < 0.0001$; *Esr2*: $t = 4.950$, $df = 4$, $p = 0.0078$; *Pgr*: $t = 39.66$, $df = 4$, $p < 0.0001$). Consistently, estradiol level was decreased in the plasma of female *Cntnap4*^{-/-} mice versus *Cntnap4*^{+/+} mice (Fig. 4h, Student's t test, $t = 2.959$, $df = 15$, $p = 0.0098$).

To further evaluate the molecular mechanisms of *Cntnap4*, we verified the ablation of *Cntnap4* (Fig. 5a, Student's t test, $t = 33.14$, $df = 10$, $p < 0.0001$; Fig. 5b, Student's t test, $t = 9.739$, $df = 10$, $p < 0.0001$) and to detect the immediate reaction of neurons, we then examined the numbers of immediate early gene c-Fos+ and palvalbumin (PV)+ neurons within 90 min in the BLA and PFC of male *Cntnap4*^{-/-} mice tested fear conditioning. Decreased c-Fos + neurons and increased PV+ neurons were observed in the BLA in male *Cntnap4*^{-/-} as compared with *Cntnap4*^{+/+} mice (Fig. 5c, Student's t test, c-Fos+: $t = 4.766$, $df = 10$, $p = 0.0008$; PV+: $t = 2.637$, $df = 10$, $p = 0.0249$). In contrast, neither c-Fos + nor PV+ neurons were changed in the PFC in male *Cntnap4*^{-/-} as compared with *Cntnap4*^{+/+} mice (Fig. 5d). Consistently, the expression of GABA_A type receptor family members GABA_ARα1, GABA_ARα2 and GABA_ARβ3 were decreased in the BLA in male

Cntnap4^{-/-} mice (Fig. 5e, Student's t test, GABA_ARα1: $t = 3.816$, $df = 10$, $p = 0.0034$; GABA_ARα2: $t = 4.419$, $df = 10$, $p = 0.0013$; GABA_ARα5: $t = 1.473$, $df = 10$, $p = 0.1716$; GABA_ARβ3: $t = 3.407$, $df = 10$, $p = 0.0067$; GABA_BR1: $t = 0.7145$, $df = 10$, $p = 0.4913$). Furthermore, the expression of GABA_ARα5 and GABA_ARβ3 were increased, while GABA_BR1 was decreased in the PFC in male *Cntnap4*^{-/-} mice (Fig. 5f, Student's t test, GABA_ARα1: $t = 0.6636$, $df = 10$, $p = 0.5219$; GABA_ARα2: $t = 1.173$, $df = 10$, $p = 0.2681$; GABA_ARα5: $t = 2.239$, $df = 10$, $p = 0.0491$; GABA_ARβ3: $t = 2.413$, $df = 10$, $p = 0.0365$; GABA_BR1: $t = 2.706$, $df = 10$, $p = 0.0221$). Somewhat different results were observed in female mice, for which *Cntnap4* was verified to be ablated in the BLA and PFC and the expression levels of GABA_ARα2, GABA_ARα5 and GABA_ARβ3 were enhanced in the BLA in *Cntnap4*^{-/-} mice (Supplementary Fig. S8a, Student's t test, $t = 3.872$, $df = 4$, $p = 0.0180$; Supplementary Fig. S8b, Student's t test, $t = 5.037$, $df = 4$, $p = 0.0073$; Supplementary Fig. S8c, GABA_ARα1: $t = 0.5698$, $df = 4$, $p = 0.5993$; GABA_ARα2: $t = 3.500$, $df = 4$, $p = 0.0249$; GABA_ARα5: $t = 3.727$, $df = 4$, $p = 0.0203$; GABA_ARβ3: $t = 3.607$,




Fig. 4: Transcriptome analysis of amygdala DEGs in female *Cntnap4*^{-/-} mice. (a) PCA score plots revealing a distinct separation of components in *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (b) Volcano plot showing the DEGs between *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. (c) KEGG pathways enriched by upregulated DEGs in *Cntnap4*^{-/-} mice compared with *Cntnap4*^{+/+} mice. The GABAergic synapse is highlighted in red. (d) Hierarchical clustering of 15 upregulated DEGs enriched in GABAergic synapse and 14 downregulated DEGs enriched in the cellular hormone metabolic process. (e) The mRNA expressions of *Car2*, *Gabra1*, *Gabrb2*, *Gabrg1*, *Gabrg2*, *Kif5b*, *Slc38a2*, *Gls2*, *Gls*, *Slc38a1*, *Gabrr2*, and *Gabrg3* in the amygdala of male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. *n* = 3. (f) Representative GO pathways enriched by downregulated DEGs. (g) The mRNA expressions of *Esr1*, *Esr2*, *Pgr*, and *Ar* in the amygdala of male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. *n* = 3. (h) The estradiol levels in the plasma of female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. *n* = 9 and 8 for *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. Results are expressed as the mean ± SEM. ***p* < 0.01 vs. *Cntnap4*^{+/+} mice. Statistical significance was determined by Student's *t*-test.

df = 4, *p* = 0.0226; GABA_BR1: *t* = 0.1606, *df* = 4, *p* = 0.8802). However, none of the GABA_A and GABA_B type receptors were changed in the PFC in female *Cntnap4*^{-/-} mice (Supplementary Fig. S8d). These results suggest that dynamic GABA receptor expression patterns and decreased amygdaloid GABA_A receptors in male *Cntnap4*^{-/-} mice may underlie the effects on GABAergic transmission, though the contribution of GABA_A receptors may be incrementally less in females. Collectively, the findings from electrophysiological recording, transcriptome analysis and molecular biology reveal that GABAergic transmission in male mice is disturbed upon *Cntnap4* deletion.

Male *Cntnap4*^{-/-} mice have reduced levels of gut microbiota *Lactobacillus*

Altered gut microbiota is critical in modulating behaviour in ASD.⁴⁴⁻⁴⁷ Therefore, we explored changes in the

gut microbiota in male and female *Cntnap4* deficient mice. The levels of α-diversity (Shannon and Simpson) and β-diversity were decreased in male *Cntnap4*^{-/-} compared with *Cntnap4*^{+/+} mice (Fig. 6a and b, Student's *t* test, Shannon: *p* = 0.036; Simpson: *p* = 0.026; β-diversity: *p* = 0.004). In contrast, other α-diversity, including ACE, chao1, observed species and PD whole tree, showed no obvious differences between male or female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice (Fig. 6a). Principal component analysis (PCA) and PCoA plots displayed the distribution of individuals in these two groups (Supplementary Fig. S9a-d), and Venn diagrams showed the overlap of differential microbiota compositions between male or female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice (Fig. 6c). We evaluated the grouped relative microbiota abundance at the phylum level (Supplementary Fig. S10a and 11a), and we also showed the differential gut microbiota and phylogenetic




Fig. 5: GABA_A receptor expression is reduced in the BLA of male Cntnap4^{-/-} mice. (a and b) Protein expression of Cntnap4 in the BLA and PFC of Cntnap4^{+/+} and Cntnap4^{-/-} mice. *n* = 6. (c and d) Immunofluorescent staining and quantitative analysis of PV⁺ and c-Fos⁺ neurons in the BLA and PFC of Cntnap4^{+/+} and Cntnap4^{-/-} mice. *n* = 5–6. Scale bar = 200 μm. (e and f) Protein expression of GABA_ARα1, GABA_ARα2, GABA_ARα5, GABA_ARβ3 and GABA_BR1 in the BLA and PFC of Cntnap4^{+/+} and Cntnap4^{-/-} mice. *n* = 6. Results are expressed as the mean ± SEM. ***p* < 0.01, **p* < 0.05 vs. Cntnap4^{+/+} mice. Statistical significance was determined by Student’s *t*-test.

relationships of species at the genus level in male and female Cntnap4^{+/+} and Cntnap4^{-/-} mice (Fig. 6d–g). Notably, *Lactobacillus* and *Lachnospiraceae_NK4A136_group* were the top hits in male and female Cntnap4^{-/-} compared with Cntnap4^{+/+} mice (Fig. 6d–g, Fig. 7a and b). We further listed the top 10 differential gut microbiota at the genus level in both male and female Cntnap4^{+/+} and Cntnap4^{-/-} mice (Fig. 7c, Student’s *t* test, *Lactobacillus*: *p* = 0.0407, *Akkermansia*: *p* = 0.0191, *Alistipes*: *p* = 0.0269, *unidentified Ruminococcaceae*: *p* = 0.0158, *Odoribacter*: *p* = 0.0440, *Mycoplasma*: *p* = 0.0329, *Paraprevotella*: *p* = 0.0069, *Erysipelatoclostridium*: *p* = 0.0160, *Lactococcus*: *p* = 0.0075, *unidentified Cyanobacteria*: *p* = 0.0369; Fig. 7d, Student’s *t* test, *Lachnospiraceae_NK4A136_group*: *p* = 0.0019, *Helicobacter*: *p* = 0.0079, *Escherichia-Shigella*: *p* = 0.0179, *Bacteroides*: *p* = 0.0299, *Lachnospiraceae_UCG-001*: *p* = 0.0489, *Colidextribacter*: *p* = 0.0060, [*Eubacterium*] *_xylanophilum_group*: *p* = 0.0030, *Roseburia*: *p* = 0.0079, *Parasutterella*, *p* = 0.0010, *Butyrivococcus*: *p* = 0.0229). Regarding male Cntnap4^{-/-} mice, *L. reuteri* and *L. salivarius* were identified as the major reduced *Lactobacillus* components at the species level (Fig. 7e, Student’s *t* test, *L. reuteri*: *t* = 2.265, *df* = 17, *p* = 0.0369;

Supplementary Fig. S10b, Student’s *t* test, *L. salivarius*: *t* = 2.329, *df* = 17, *p* = 0.0325), while *Bacteroides acidifaciens* was found to be decreased and *Streptococcus hyointestinalis* was found to be increased (Supplementary Fig. S10c and d, Student’s *t* test, *Bacteroides acidifaciens*: *t* = 2.406, *df* = 17, *p* = 0.0278; *S. hyointestinalis*: *t* = 4.456, *df* = 17, *p* = 0.0003). Regarding female Cntnap4^{-/-} mice, *Helicobacter typhlonius*, *Escherichia coli*, *Parabacteroides goldsteinii*, and *Bacteroides vulgatus* were identified the top hits of decreased microbiota at the species level (Fig. 7f, Student’s *t* test, *H. typhlonius*: *t* = 2.548, *df* = 17, *p* = 0.0208; Supplementary Fig. S11b–d, Student’s *t* test, *E. coli*: *t* = 2.118, *df* = 17, *p* = 0.0492; *P. goldsteinii*: *t* = 2.239, *df* = 17, *p* = 0.0388; *Bacteroides vulgatus*: *t* = 3.243, *df* = 17, *p* = 0.0048). Functional analysis suggested that the majority of the differential gut microbiota in male and female Cntnap4^{-/-} mice was enriched in “Environmental information processing”, “Genetic information processing” (such as transfer RNA biogenesis, replication, recombination and repair proteins, aminoacyl RNA biosynthesis) and “Metabolism” (such as mitochondrial biogenesis, pyruvate metabolism, glycolysis/gluconeogenesis) pathways (Fig. 7g and h, and




Fig. 6: *Cntnap4* deficiency alters the gut microbiota composition. (a and b) α -diversity (ACE, Chao1, observed species, PD whole tree, Shannon and Simpson) and β -diversity in gut microbiota. (c) Venn diagram showing the overlap in microbiota composition between male and female *Cntnap4*^{-/-} and *Cntnap4*^{+/+} mice. (d) The differential gut microbiota between male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice at the genus level. The abundance of *Lactobacillus* was significantly decreased at the genus level in *Cntnap4*^{-/-} mice (highlighted in red in d). (e) Phylogenetic relationships of species at the genus level in male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. *Lactobacillus* was framed. (f) The differential gut microbiota between female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice at the genus level. The abundance of the *Lachnospiraceae_NK4A136_group* was significantly decreased at the genus level in *Cntnap4*^{-/-} mice (highlighted in red in f). (g) Phylogenetic relationships of species at the genus level in female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. *Lachnospiraceae_NK4A136_group* was framed. Results are expressed as the mean \pm SEM. *n* = 11 and 8 for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice; *n* = 10 and 9 for female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. ***p* < 0.01, **p* < 0.05 vs. *Cntnap4*^{+/+} mice. Statistical significance was determined by Student's *t*-test.

Supplementary Fig. S10e and f, Fig. 11e and f). However, the differential gut microbiotas seemed not to participate in exactly same pathways, because half the pathways (17/34) were opposite in male and female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice (Fig. 7g and h).

These results suggest that *Lactobacillus* is the predominant form of reduced gut microbiota in male *Cntnap4*^{-/-} mice, and that its reduced levels may be responsible for the impaired fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice.

Treatment with *L. reuteri* rescues fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice

Given that *L. reuteri* has been reported to relieve ASD-related behavioural abnormalities,⁵⁷ we wondered whether it could rescue impaired fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice. To evaluate this possibility, we fed male *Cntnap4*^{-/-} mice with PBS or *L. reuteri* for 4 weeks (Fig. 8a). We confirmed the colonization of the gastrointestinal tract




Fig. 7: The faecal *L. reuteri* level is decreased in male *Cntnap4^{-/-}* mice. (a and b) Relative abundance of the top 10 differential gut microbiota at the genus level in male *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. *Lactobacillus* was significantly decreased at the genus level in male *Cntnap4^{-/-}* mice (highlighted in red) compared with *Cntnap4^{+/+}* mice, and *Lachnospiraceae_NK4A136_group* was significantly decreased at the genus level in female *Cntnap4^{-/-}* mice (highlighted in blue) compared with *Cntnap4^{+/+}* mice. (c) The abundance of *Lactobacillus*, *Akkermansia*, *Alistipes*, unidentified Ruminococcaceae, *Odoribacter*, *Mycoplasma*, *Paraprevotella*, *Erysipelatoclostridium*, *Lactococcus*, and unidentified Cyanobacteria at the genus level in male *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. (d) The abundance of *Lachnospiraceae_NK4A136_group*, *Helicobacter*, *Escherichia-Shigella*, *Bacteroides*, *Lachnospiraceae_UCG-001*, *Colidextribacter*, *[Eubacterium]_xylanophilum_group*, *Roseburia*, *Parasutterella*, and *Butyricoccus* at the genus level in female *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. (e and f) The abundance of *L. reuteri* and *Helicobacter typhlonius* at the species levels in male and female *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. (g and h) The pathways enriched by the differential gut microbiota in male and female *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. Results are expressed as the mean \pm SEM. $n = 11$ and 8 for male *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice; $n = 10$ and 9 for female *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice. $**p < 0.01$, $*p < 0.05$ vs. *Cntnap4^{+/+}* mice. Statistical significance was determined by Student's t-test.

by *L. reuteri* by examining its mRNA expression in the colon (Fig. 8b, $p < 0.0001$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{+/+}* mice, $p = 0.0229$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice). There were no obvious effects on the contextual test and pre-tone phase (Fig. 8c and d); however, *L. reuteri* reversed tone-cued fear conditioning in *Cntnap4^{-/-}* mice (Fig. 8e, $p = 0.0017$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0128$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice). *L. reuteri* treatment also increased the social interaction ratio in the interaction zone and decreased it in the corner zone, alongside enhanced duration in the interaction zone under the target condition (Fig. 8f–h, $p = 0.0010$, 0.0399 , and 0.0005 for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment; $p = 0.0149$, 0.0472 , and 0.0449 for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice, respectively). Furthermore, *L. reuteri* did not affect the behavioural performance in the EPM, Y maze and TST (Supplementary Fig. S12a–e). Remarkably, however, *L. reuteri* reversed the decreased sIPSC amplitude in the BLA in *Cntnap4^{-/-}* mice (Fig. 8i and j, $p = 0.0191$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0186$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{+/+}* mice, $p = 0.0066$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice, $p = 0.0060$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon *L. reuteri* treatment). *L. reuteri* treatment also showed no obvious effects on the sIPSC frequency in the BLA in male *Cntnap4^{-/-}* mice (Fig. 8k) but decreased the sIPSC amplitude and frequency in the PrL in male *Cntnap4^{-/-}* mice (Fig. 8l–n, $p = 0.0483$ and 0.0010 for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice, respectively). Moreover, no obvious changes were observed in the sEPSC amplitude and frequency in the BLA and PrL of *Cntnap4^{-/-}* mice upon *L. reuteri* treatment (Supplementary Fig. S13a–f).

For additional evidence of the effects of *L. reuteri* treatment, we examined the neurons in male *Cntnap4^{-/-}* mice. *L. reuteri* treatment increased c-Fos + neurons and decreased PV+/c-Fos + colocalized neurons in the BLA (Fig. 9a–c, Fig. 9b: $p = 0.0005$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0014$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice; Fig. 9c: $p = 0.0285$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0285$ for *L. reuteri* vs. PBS treatment in *Cntnap4^{-/-}* mice). On the other hand, there were no obvious effects on the PV+ and c-Fos + neurons in the PFC in male *Cntnap4^{-/-}* mice (Supplementary Fig. S14a–d). Furthermore, *L. reuteri* treatment did not alter the levels of α -diversity, including Chao1, Shannon and Simpson diversity (Fig. 9d and e, Supplementary Fig. S15a and b). However, it significantly increased the relative abundance of *L. reuteri*, suggesting that *L. reuteri* treatment mediates a change in the microbial composition of the host (Fig. 9f, Student's *t* test, $t = 2.740$, $df = 10$, $p = 0.0208$). Moreover, *L. reuteri* treatment also increased the faecal *Ileibacterium valens*

level and decreased the *Mucispirillum schaedleri* and *P. goldsteinii* levels in male *Cntnap4^{-/-}* mice (Fig. 9g–i, *I. valens*: Student's *t* test, $t = 2.242$, $df = 10$, $p = 0.0488$; *M. schaedleri*: Student's *t* test, $t = 2.391$, $df = 10$, $p = 0.0379$; *P. goldsteinii*: Student's *t* test, $t = 2.547$, $df = 10$, $p = 0.0290$). Collectively, these observations reveal that *L. reuteri* treatment rescues impaired tone-cued fear conditioning and GABAergic synaptic transmission in male *Cntnap4^{-/-}* mice.

Transplantation of the faecal microbiota from *Cntnap4^{+/+}* mice restores the fear memory and GABAergic transmission in male *Cntnap4^{-/-}* mice

Since microbiota transfer therapy is a potential tool for treatment of ASD,⁶⁴ we then performed FMT experiments to evaluate if the microbes from *Cntnap4^{+/+}* mice could rescue the fear memory and GABAergic transmission in male *Cntnap4^{-/-}* mice. Male *Cntnap4^{+/+}* and *Cntnap4^{-/-}* mice were gavaged the faecal microbiota from 8-week-old male wild type C57BL/6J mice for 1 week (Fig. 10a). We found FMT also increased the colonization of *L. reuteri* in the colon (Fig. 10b, $p = 0.0242$ for FMT vs. PBS treatment in *Cntnap4^{+/+}* mice, $p = 0.0312$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice). Here, FMT increased the time male *Cntnap4^{+/+}* mice spent in the centre zone of the open field (Supplementary Fig. S16, $p = 0.0130$ for FMT vs. PBS treatment in *Cntnap4^{+/+}* mice). During the fear conditioning test, there were no obvious effects on the contextual test or pre-tone phase (Fig. 10c and d), while FMT rescued tone-cued fear conditioning in *Cntnap4^{-/-}* mice (Fig. 10e, $p < 0.0001$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0136$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice). FMT also enhanced the social interaction ratio in the interaction zone (Fig. 10f, $p = 0.0201$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0361$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice) and decreased it in the corner zone (Fig. 10g, $p = 0.0056$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0014$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice). The duration of *Cntnap4^{-/-}* mice in the interaction zone was reversed upon FMT intervention with the target (Fig. 10h, $p = 0.0042$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0005$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice). Consistently, FMT also reversed the decreased sIPSC amplitude in the BLA in *Cntnap4^{-/-}* mice (Fig. 10i and j, $p = 0.0211$ for *Cntnap4^{+/+}* mice vs. *Cntnap4^{-/-}* mice upon PBS treatment, $p = 0.0268$ for FMT vs. PBS treatment in *Cntnap4^{-/-}* mice). Furthermore, FMT increased the sIPSC frequency in the BLA in male *Cntnap4^{+/+}* mice (Fig. 10k, $p = 0.0414$ for FMT vs. PBS treatment in *Cntnap4^{+/+}* mice). FMT showed no obvious effects on the sIPSC amplitude and frequency in the PrL in male *Cntnap4^{-/-}* mice (Fig. 10l–n). Thus,




Fig. 8: *L. reuteri* treatment rescues tone-cued fear conditioning and amygdaloid GABAergic transmission in male *Cntnap4*^{-/-} mice. (a) Experimental design for *L. reuteri* administration in male *Cntnap4*^{-/-} mice. (b) The mRNA expressions of *L. reuteri* in the colon of male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or *L. reuteri*. *n* = 3 per group. $F_{1, 8} = 26.34$, $p = 0.0009$ for treatment-genotype interaction; $F_{1, 8} = 109.3$, $p < 0.0001$ for genotype; $F_{1, 8} = 26.65$, $p = 0.0009$ for treatment. (c and d) Freezing levels of male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or *L. reuteri* in the contextual test before the tone was applied. *n* = 9 per group. (c) $F_{1, 32} = 0.3493$, $p = 0.5586$ for treatment-genotype interaction; $F_{1, 32} = 1.128$, $p = 0.2962$ for genotype; $F_{1, 32} = 1.114$, $p = 0.2990$ for treatment. (d) $F_{1, 32} = 4.575e-005$, $p = 0.9946$ for treatment-genotype interaction; $F_{1, 32} = 0.2412$, $p = 0.6267$ for genotype; $F_{1, 32} = 0.1664$, $p = 0.6860$ for treatment. (e) *L. reuteri* increased the freezing time in male *Cntnap4*^{-/-} mice in tone-cued fear conditioning. *n* = 9 per group. $F_{1, 32} = 14.04$, $p = 0.0007$ for treatment-genotype interaction; $F_{1, 32} = 0.7930$, $p = 0.3798$ for genotype; $F_{1, 32} = 3.848$, $p = 0.0586$ for treatment. (f and g) SI ratio in the interaction and corner zone for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or *L. reuteri*. *n* = 9 per group. (f) $F_{1, 32} = 7.606$, $p = 0.0095$ for treatment-genotype interaction; $F_{1, 32} = 3.218$, $p = 0.0823$ for genotype; $F_{1, 32} = 10.35$, $p = 0.0030$ for treatment. (g) $F_{1, 32} = 2.868$, $p = 0.1000$ for treatment-genotype interaction; $F_{1, 32} = 4.727$, $p = 0.0372$ for genotype; $F_{1, 32} = 5.186$, $p = 0.0296$ for treatment. (h) Time spent in the interaction zone for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or *L. reuteri* with a target. *n* = 9 per group. $F_{1, 32} = 5.741$, $p = 0.0226$ for treatment-genotype interaction; $F_{1, 32} = 2.256$, $p = 0.1429$ for genotype; $F_{1, 32} = 15.41$, $p = 0.0004$ for treatment. (i and l) Representative traces of GABA receptor-mediated sIPSCs in the BLA and PrL. All sIPSCs were recorded at a holding potential of -70 mV. (j and m) Cumulative frequency plots (left) and quantitative analysis (right) of the amplitude of GABA receptor-mediated sIPSCs in the BLA and PrL. (j) $F_{1, 47} = 21.13$, $p < 0.0001$ for treatment-genotype interaction; $F_{1, 47} = 0.1655$, $p = 0.6860$ for genotype; $F_{1, 47} = 0.02387$, $p = 0.8779$ for treatment. (m) $F_{1, 55} = 0.03771$, $p = 0.8467$ for treatment-genotype interaction; $F_{1, 55} = 11.57$, $p = 0.0013$ for genotype; $F_{1, 55} = 0.06133$, $p = 0.8053$ for treatment. (k and n) Cumulative frequency plots of the interevent interval (left) and quantitative analysis of the frequency of GABA receptor-mediated




Fig. 9: *L. reuteri* treatment increases c-Fos + neurons in the BLA in male *Cntnap4*^{-/-} mice. (a–c) Immunofluorescent staining and quantitative analysis of c-Fos + neurons and the PV⁺/c-Fos⁺ colocalization ratio in the BLA of *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or *L. reuteri*. (b) $F_{1, 20} = 13.01$, $p = 0.0018$ for treatment–genotype interaction; $F_{1, 20} = 6.882$, $p = 0.0163$ for genotype; $F_{1, 20} = 10.75$, $p = 0.0038$ for treatment. (c) $F_{1, 20} = 3.097$, $p = 0.0937$ for treatment–genotype interaction; $F_{1, 20} = 6.654$, $p = 0.0179$ for genotype; $F_{1, 20} = 6.654$, $p = 0.0179$ for treatment. $n = 6$ per group. Scale bar = 500 μm . (d) Venn diagram showing the overlap in the differential microbiota composition between *Cntnap4*^{-/-} + PBS and *Cntnap4*^{-/-} + *L. reuteri* mice. (e) α -diversity (Chao1) in gut microbiota between *Cntnap4*^{-/-} + PBS and *Cntnap4*^{-/-} + *L. reuteri* mice. (f–i) Relative abundance of faecal *L. reuteri*, *Ileibacterium valens*, *Mucispirillum schaedleri* and *Parabacteroides goldsteinii* at the species level between *Cntnap4*^{-/-} + PBS and *Cntnap4*^{-/-} + *L. reuteri* mice. $n = 6$ per group. Results are expressed as the mean \pm SEM. ** $p < 0.01$, * $p < 0.05$ vs. *Cntnap4*^{+/+} + PBS mice (for b and c) or *Cntnap4*^{-/-} + PBS mice (for e–i); ## $p < 0.01$, # $p < 0.05$ vs. *Cntnap4*^{-/-} + PBS mice. Statistical significance was determined by two-way ANOVA + Bonferroni’s multiple comparisons test (for b and c) and Student’s *t*-test (for e–i).

FMT also restores the impaired fear conditioning and GABAergic synaptic transmission in male *Cntnap4*^{-/-} mice.

Discussion

The gut–brain axis adds a new dimension to autism therapy, as emerging evidence indicates that gut microbes skillfully modulate social and emotional behaviours. In the present study, we reveal that social behaviours, fear conditioning and GABAergic synaptic transmission are impaired in male *Cntnap4*^{-/-} mice. Based on an altered gut microbiota community after

Cntnap4 ablation, we provide evidence that *L. reuteri* treatment or faecal microbiota transplantation rescues impaired tone-cued fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice.

Previously, *Cntnap4* was found to be localized presynaptically, and its deficiency was shown to reduce the output of cortical PV⁺ GABAergic basket cells.²⁸ *Cntnap4*^{-/-} mice manifest sensory-motor gating and over-grooming, which are core symptoms of ASD.²⁸ In this study, we report that male *Cntnap4*^{-/-} mice lack a preference for novel social partners and display a social novelty recognition deficit. Furthermore, *Cntnap4* deficiency also affects tone-cued fear memory

sIPSCs (right) in the BLA and PrL. (k) $F_{1, 61} = 1.630$, $p = 0.2065$ for treatment–genotype interaction; $F_{1, 61} = 5.101$, $p = 0.0275$ for genotype; $F_{1, 61} = 1.412$, $p = 0.2393$ for treatment. (n) $F_{1, 55} = 1.070$, $p = 0.3054$ for treatment–genotype interaction; $F_{1, 55} = 19.41$, $p < 0.0001$ for genotype; $F_{1, 55} = 0.5539$, $p = 0.4599$ for treatment. 11–17 slices from $n = 4$ mice per group. Results are expressed as the mean \pm SEM. ** $p < 0.01$, * $p < 0.05$ vs. *Cntnap4*^{+/+} + PBS mice; ## $p < 0.01$, # $p < 0.05$ vs. *Cntnap4*^{-/-} + PBS mice; && $p < 0.01$ vs. *Cntnap4*^{+/+} + *L. reuteri* mice. Statistical significance was determined by two-way ANOVA + Bonferroni’s multiple comparisons test.




Fig. 10: Transplantation of the faecal microbiota rescues tone-cued fear conditioning and amygdaloid GABAergic transmission in male *Cntnap4*^{-/-} mice. (a) Experimental design for FMT administration in male *Cntnap4*^{-/-} mice. (b) The mRNA expressions of *L. reuteri* in the colon of male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice treated with PBS or FMT. $n = 3$ per group. $F_{1, 8} = 0.0173$, $p = 0.8985$ for treatment-genotype interaction; $F_{1, 8} = 26.39$, $p = 0.0009$ for genotype; $F_{1, 8} = 0.0058$, $p = 0.9413$ for treatment. (c and d) Freezing levels of male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice upon PBS treatment or FMT in the contextual test before the tone was applied. (c) $F_{1, 32} = 2.380$, $p = 0.1327$ for treatment-genotype interaction; $F_{1, 32} = 0.1382$, $p = 0.7125$ for genotype; $F_{1, 32} = 4.210$, $p = 0.0485$ for treatment. (d) $F_{1, 32} = 0.02411$, $p = 0.8776$ for treatment-genotype interaction; $F_{1, 32} = 2.853$, $p = 0.1009$ for genotype; $F_{1, 32} = 0.03214$, $p = 0.8588$ for treatment. (e) FMT increased the freezing time in male *Cntnap4*^{-/-} mice in tone-cued fear conditioning. $F_{1, 32} = 5.313$, $p = 0.0278$ for treatment-genotype interaction; $F_{1, 32} = 4.698$, $p = 0.0377$ for genotype; $F_{1, 32} = 30.59$, $p < 0.0001$ for treatment. (f and g) SI ratio in the interaction and corner zone for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice upon PBS treatment or FMT. (f) $F_{1, 32} = 7.487$, $p = 0.0101$ for treatment-genotype interaction; $F_{1, 32} = 1.397$, $p = 0.2460$ for genotype; $F_{1, 32} = 3.108$, $p = 0.0875$ for treatment. (g) $F_{1, 32} = 13.73$, $p = 0.0008$ for treatment-genotype interaction; $F_{1, 32} = 3.800$, $p = 0.0600$ for genotype; $F_{1, 32} = 2.329$, $p = 0.1368$ for treatment. (h) Time spent in the interaction zone for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice upon PBS treatment or FMT with a target. $F_{1, 32} = 7.320$, $p = 0.0108$ for treatment-genotype interaction; $F_{1, 32} = 12.05$, $p = 0.0015$ for genotype; $F_{1, 32} = 7.170$, $p = 0.0116$ for treatment. $n = 8, 9, 9, 10$ for *Cntnap4*^{+/+} + PBS, *Cntnap4*^{-/-} + PBS, *Cntnap4*^{-/-} + FMT, *Cntnap4*^{+/+} + FMT, respectively. (i and l) Representative traces of GABA receptor-mediated sIPSCs in the BLA and PrL. All sIPSCs were recorded at a holding potential of -70 mV. (j and m) Cumulative frequency plots (left) and quantitative analysis (right) of the amplitude of GABA receptor-mediated sIPSCs in the BLA and PrL. (j) $F_{1, 60} = 0.2793$, $p = 0.5991$ for treatment-genotype interaction;

processing in male mice. The amygdala is critical for input and processing of emotional memories, especially including fear memory acquisition, consolidation and extinction,^{11,65–67} and amygdala projection neurons are primarily innervated by GABAergic interneurons. Amygdaloid GABAergic mechanisms, such as neuregulin 1-ErbB4 and TMEM16B/ANO2 signalling, contribute significantly to fear memory processing.^{12,68,69} As *Cntnap4* is expressed in interneurons in the amygdala,³⁰ our results support a role for *Cntnap4* in GABAergic transmission and tone-cued fear conditioning because nearly 90% of mature cortical PV+ interneurons express *Cntnap4*,²⁸ and amygdala pyramidal neurons are regulated by local GABAergic interneurons (~10% of the neuronal population). *Cntnap4* loss reduces GABA release and affects GABAergic receptors expressed in amygdala pyramidal neurons in the BLA. Accordingly, the sIPSC amplitude but not frequency was decreased in male *Cntnap4*^{-/-} mice. Additionally, RNA-seq and molecular biological results showed disturbed GABA_A type receptor expression upon *Cntnap4* deficiency. Thus, our results may provide new evidence for *Cntnap4* loss participating in amygdala GABAergic transmission chaos in ASD. In this study, we observed that *Cntnap4* deficiency induced decreased GABA-related gene or receptor expression and reduced GABAergic transmission, alongside increased PV+ cells in the BLA. To test the role of GAD67 in GABAergic neuron, previously, Fujihara et al. generated *PV-Cre*, *GAD67^{lox/lox}* (homozygous) and *PV-Cre*, and *GAD67^{lox/+}* (heterozygous) mice.⁷⁰ They found that homozygous *GAD67* deletion in PV neurons leads to a reduction in GAD67 and GABA immunoreactivities and substantial increases in PV immunoreactivity.⁷⁰ Since GAD-67-mediated GABA synthesis shapes the PV-synaptic innervations during the maturation of inhibitory circuits,⁷¹ they speculated that this effect may contribute to the excitation of pyramidal neurons and induce compensatory responses in homozygous *PV-Cre*; *GAD67^{lox/lox}* mice.⁷⁰ Because almost all *Cntnap4*⁺ cells within the somatosensory cortex are GAD67 positive and almost all mature PV cells (~94%) express *Cntnap4*,²⁸ the increased populations of PV+ neurons mediated by *Cntnap4* deficiency may be also a compensatory change in response to the decrease in GABA-related gene or receptor expression.

Although the majority of neurons (at least 85%) in the BLA projecting to the prefrontal cortex or ventral

striatum are excitatory neurons,⁷² we did not observe apparent changes in sEPSC amplitude and frequency in the BLA and PFC of *Cntnap4*^{-/-} mice. On the one hand, given that *Cntnap4* is mainly expressed in interneurons, its ablation exerts less effect on excitatory synaptic transmission. On the other hand, these results may indicate that the BLA-PFC projection is unaltered upon *Cntnap4* knockout. Nevertheless, we still need conditional *Cntnap4* knockout in PV+ neurons to draw this conclusion. Furthermore, we acknowledge that we did not observe the social deficits, impaired fear conditioning, together with disturbed GABAergic transmission in female *Cntnap4*^{-/-} mice. Mechanistically, unlike the downregulated GABAergic transmission in male *Cntnap4*^{-/-} mice, we confirmed the increased GABAergic receptor expression in the amygdala of female *Cntnap4*^{-/-} mice alongside reduced estradiol and oestrogen receptor levels. Oestrogen is critical in regulating neuronal activity and animal behaviour associated with ASD.⁷³ Previously, oestrogen receptors were found to be colocalized in GABAergic neurons,^{74,75} and there are dynamic results regarding oestrogen regulating GABAergic synapse in the brain. In the medial preoptic area and other hypothalamus areas, oestrogen acts to increase GABA release and reuptake as well as GABA_A receptor expression.^{76–78} However, in the amygdala and hippocampus, oestrogen acts to suppress GABAergic transmission by inhibiting GABA_A receptors expression.^{77,79} We conclude that *Cntnap4* ablation decreases estradiol levels, and thus increases GABAergic synapses, which may compromise the dysfunctional GABAergic transmission observed in male *Cntnap4*^{-/-} mice. Nevertheless, female *Cntnap4*^{-/-} mice also display hair loss due to overgrooming and show impaired spontaneous alterations in the Y maze test, suggesting that their working memory may be damaged. Indeed, *Cntnap4* deletion may impair hippocampal learning and memory in female mice, given that we and other groups have revealed that *Cntnap4* plays an important role in aging-related diseases, such as PD and AD.^{36,38} Thus, the effects of hormonal influences and neural circuit development on GABAergic transmission result in the sex differences in processing fear memory.⁸⁰

Notably, we demonstrated that *L. reuteri* treatment rescues impaired tone-cued fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice. Recently, manipulating gut microbiota has been shown to provide an attractive approach in treating neurological

$F_{1, 60} = 14.49$, $p = 0.0003$ for genotype; $F_{1, 60} = 13.58$, $p = 0.0005$ for treatment. (m) $F_{1, 68} = 0.0006$, $p = 0.9803$ for treatment-genotype interaction; $F_{1, 68} = 0.05369$, $p = 0.8175$ for genotype; $F_{1, 68} = 0.003415$, $p = 0.9536$ for treatment. (k and n) Cumulative frequency plots of the interevent interval (left) and quantitative analysis of the frequency of GABA receptor-mediated sIPSCs (right) in the BLA and PrL. (k) $F_{1, 67} = 0.2678$, $p = 0.6065$ for treatment-genotype interaction; $F_{1, 67} = 11.18$, $p = 0.0014$ for genotype; $F_{1, 67} = 3.871$, $p = 0.0533$ for treatment. (n) $F_{1, 68} = 0.03963$, $p = 0.8428$ for treatment-genotype interaction; $F_{1, 68} = 3.075$, $p = 0.0840$ for genotype; $F_{1, 68} = 1.094$, $p = 0.2993$ for treatment. 14–18 slices from $n = 4$ mice per group. Results are expressed as the mean \pm SEM. ** $p < 0.01$, * $p < 0.05$ vs. *Cntnap4*^{+/+} + PBS mice; ## $p < 0.01$, # $p < 0.05$ vs. *Cntnap4*^{-/-} + PBS mice. Statistical significance was determined by two-way ANOVA + Bonferroni's multiple comparisons test.




Fig. 11: Illustration design of this study. In the normal condition, *Lactobacillus* maintains the processing of fear memory via regulating GABAergic transmission in BLA. Upon *Cntnap4* deficiency, male mice manifest *Lactobacillus* (especially *L. reuteri*) loss and dysfunction of GABAergic transmission in BLA. Ultimately, *Lactobacillus reuteri* supplementation or faecal microbiota transplantation restores the tone-cued fear memory possibly via amelioration of amygdala GABAergic transmission.

diseases.⁸¹ Previously, ASD patients have been identified to harbour altered gut microorganisms and serious gastrointestinal problems,^{44,45} and many meaningful studies suggest that microbiota treatment is a promising intervention for ASD patients.^{47,64} Although there seems to be a shift in the general microbial composition between male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice, we focused on *L. reuteri* in this study. First, we identified *Lactobacillus* is the predominant form of reduced gut microbiota in male *Cntnap4*^{-/-} mice, and both *L. reuteri* and *L. salivarius* were decreased in male *Cntnap4*^{-/-} mice. Meanwhile, the content of *L. reuteri* was much more abundant than that of *L. salivarius*. Second, *L. reuteri* has been reported to recover social deficits in ASD models,^{57,82} and clinical trials are also on the way to evaluate *L. reuteri* interventions in ASD patients.⁸³ Although *L. salivarius* is also a probiotic candidate, it is

reported to influence the host immune system and possess anti-inflammatory properties.⁸⁴ Moreover, *L. salivarius* has been revealed to prevent inflammation in different disease models, such as intestinal and skin inflammation.^{85,86} Herein, we report that *L. reuteri* administration restores tone-cued fear conditioning, and it also enhances GABAergic transmission in male *Cntnap4*^{-/-} mice. Given that FMT is an emerging approach for the treatment of ASD,^{47,64} our data also support that FMT rescues the fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice. Our results showed that *Cntnap4*^{-/-} mice treated with *L. reuteri* were improved in the behavioural tests and brain activity, the *L. reuteri* colonization in *Cntnap4*^{-/-} mice is actually much lower than the *Cntnap4*^{+/+} mice. Considering together the transfer of fecal materials from *Cntnap4*^{+/+} to *Cntnap4*^{-/-} mice also rescued the

behaviours, it is more convincing that the entire shift of microbial composition benefits the *Cntnap4*^{-/-} mice more than *L. reuteri* itself. Our study broadens the potential role of microbiota in ASD therapy and provide insights for its potential mechanisms of action.

In summary, we provide evidence that *Cntnap4* deficiency impairs social behaviours and tone-cued fear conditioning. Altered GABAergic synaptic transmission in BLA and disturbed gut microbiota composition underlie these behavioural abnormalities. Remarkably, *L. reuteri* administration or faecal microbiota transplantation rescues impaired tone-cued fear conditioning and GABAergic transmission in male *Cntnap4*^{-/-} mice. Taken together, our findings highlight the potential of *L. reuteri* treatment as a new approach to ameliorate ASD (Fig. 11).

Contributors

Y.L.Z. designed the experiments, supervised the project, and wrote the manuscript. W.L.Z., and M.R.Z. performed the Western blotting experiments and analysed the data. J.H., and Q.L.Y. performed the electrophysiological experiments. X.D.S. analysed the electrophysiological data. F.G., and L.Y.D. performed the immunostaining. J.W.G., R.F.M., and S.H.Z. helped with animal surgery and behavioural experiments as well as data analysis. W.L.Z., and Y.L.Z. have directly accessed and verified the underlying data reported in the manuscript. All authors read and approved the final manuscript.

Data sharing

All data needed to evaluate the conclusions in the paper are presented in the paper and/or the Supplementary Materials. RNA-seq data used in this study are available under GEO: GSE208542 for male *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice and GSE208397 for female *Cntnap4*^{+/+} and *Cntnap4*^{-/-} mice. Additional data related to this paper may be requested from the corresponding author.

Declaration of interests

The authors declare no competing interests.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82174468 and 82101325), Science and Technology Planning Project of Guangzhou (No. 201904010238), Guangzhou Medical University Discipline Construction Funds (Basic Medicine, No. JCXKJS2022A09), and China Postdoctoral Science Foundation (No. 2021M700951).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.ebiom.2022.104323>.

References

- Black DW, Grant JE, American Psychiatric Association. DSM-5 Guidebook: The Essential Companion to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 1st ed.
- Lai MC, Lombardo MV, Baron-Cohen S. Autism. *Lancet*. 2014;383(9920):896–910.
- Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. *Lancet*. 2018;392(10146):508–520.
- Zwaigenbaum L, Penner M. Autism spectrum disorder: advances in diagnosis and evaluation. *BMJ*. 2018;361:k1674.
- Wang SS, Kloth AD, Badura A. The cerebellum, sensitive periods, and autism. *Neuron*. 2014;83(3):518–532.
- Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature*. 2011;474(7351):380–384.
- Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. *Trends Neurosci*. 2008;31(3):137–145.
- Aylward EH, Minshew NJ, Goldstein G, et al. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. *Neurology*. 1999;53(9):2145–2150.
- Schumann CM, Amaral DG. Stereological analysis of amygdala neuron number in autism. *J Neurosci*. 2006;26(29):7674–7679.
- Schumann CM, Barnes CC, Lord C, Courchesne E. Amygdala enlargement in toddlers with autism related to severity of social and communication impairments. *Biol Psychiatr*. 2009;66(10):942–949.
- Ehrlich I, Humeau Y, Grenier F, Ciochi S, Herry C, Luthi A. Amygdala inhibitory circuits and the control of fear memory. *Neuron*. 2009;62(6):757–771.
- Lu Y, Sun XD, Hou FQ, et al. Maintenance of GABAergic activity by neuregulin 1-ErbB4 in amygdala for fear memory. *Neuron*. 2014;84(4):835–846.
- Markram K, Rinaldi T, La Mendola D, Sandi C, Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. *Neuropsychopharmacology*. 2008;33(4):901–912.
- Gilbert J, O'Connor M, Temple S, et al. NEXMIF/KIDLIA knockout mouse demonstrates autism-like behaviours, memory deficits, and impairments in synapse formation and function. *J Neurosci*. 2020;40(1):237–254.
- Huang L, Wang J, Liang G, et al. Upregulated NMDAR-mediated GABAergic transmission underlies autistic-like deficits in Htr3a knockout mice. *Theranostics*. 2021;11(19):9296–9310.
- Banerjee A, Luong JA, Ho A, Saib AO, Ploski JE. Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment. *Mol Autism*. 2016;7:16.
- Ronald A, Hoekstra RA. Autism spectrum disorders and autistic traits: a decade of new twin studies. *Am J Med Genet B Neuropsychiatr Genet*. 2011;156B(3):255–274.
- Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat Genet*. 2003;34(1):27–29.
- Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet*. 2007;39(1):25–27.
- Berkel S, Marshall CR, Weiss B, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. *Nat Genet*. 2010;42(6):489–491.
- Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypes and Rett syndrome phenotypes. *Nature*. 2010;468(7321):263–269.
- Jung EM, Moffat JJ, Liu J, Dravid SM, Gurumurthy CB, Kim WY. Arid1b haploinsufficiency disrupts cortical interneuron development and mouse behaviour. *Nat Neurosci*. 2017;20(12):1694–1707.
- Paulsen B, Velasco S, Kedaigle AJ, et al. Autism genes converge on asynchronous development of shared neuron classes. *Nature*. 2022;602(7896):268–273.
- Bernier R, Golzio C, Xiong B, et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell*. 2014;158(2):263–276.
- Yan Y, Tian M, Li M, et al. ASH1L haploinsufficiency results in autistic-like phenotypes in mice and links Eph receptor gene to autism spectrum disorder. *Neuron*. 2022;110(7):1156–11572 e9.
- Penagarikano O, Abrahams BS, Herman EI, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell*. 2011;147(1):235–246.
- Hoffman EJ, Turner KJ, Fernandez JM, et al. Estrogens suppress a behavioural phenotype in zebrafish mutants of the autism risk gene, CNTNAP2. *Neuron*. 2016;89(4):725–733.
- Karayannis T, Au E, Patel JC, et al. *Cntnap4* differentially contributes to GABAergic and dopaminergic synaptic transmission. *Nature*. 2014;511(7508):236–240.
- Einheber S, Zanazzi G, Ching W, et al. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. *J Cell Biol*. 1997;139(6):1495–1506.

- 30 Spiegel I, Salomon D, Erne B, Schaeren-Wiemers N, Peles E. Caspr3 and caspr4, two novel members of the caspr family are expressed in the nervous system and interact with PDZ domains. *Mol Cell Neurosci.* 2002;20(2):283–297.
- 31 Ho A, Morishita W, Hammer RE, Malenka RC, Sudhof TC. A role for Mints in transmitter release: Mint 1 knockout mice exhibit impaired GABAergic synaptic transmission. *Proc Natl Acad Sci USA.* 2003;100(3):1409–1414.
- 32 Atasoy D, Schoch S, Ho A, et al. Deletion of CASK in mice is lethal and impairs synaptic function. *Proc Natl Acad Sci USA.* 2007;104(7):2525–2530.
- 33 Yin FT, Futagawa T, Li D, et al. Caspr4 interaction with LNX2 modulates the proliferation and neuronal differentiation of mouse neural progenitor cells. *Stem Cell Dev.* 2015;24(5):640–652.
- 34 Tuncay IO, Parmalee NL, Khalil R, et al. Analysis of recent shared ancestry in a familial cohort identifies coding and noncoding autism spectrum disorder variants. *NPJ Genom Med.* 2022;7(1):13.
- 35 Costa CIS, da Silva Montenegro EM, Zarrei M, et al. Copy number variations in a Brazilian cohort with autism spectrum disorders highlight the contribution of cell adhesion genes. *Clin Genet.* 2022;101(1):134–141.
- 36 Zhang W, Zhou M, Lu W, et al. CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes. *Theranostics.* 2020;10(7):3000–3021.
- 37 Shangguan Y, Xu X, Ganbat B, et al. CNTNAP4 impacts epilepsy through GABAA receptors regulation: evidence from temporal lobe epilepsy patients and mouse models. *Cerebr Cortex.* 2018;28(10):3491–3504.
- 38 Iakoubov L, Mossakowska M, Szwed M, Duan Z, Sesti F, Puzianowska-Kuznicka M. A common copy number variation (CNV) polymorphism in the CNTNAP4 gene: association with aging in females. *PLoS One.* 2013;8(11):e79790.
- 39 Makkar SR, Zhang SQ, Cranney J. Behavioural and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. *Neuropsychopharmacology.* 2010;35(8):1625–1652.
- 40 Tsuang MT, Bar JL, Stone WS, Faraone SV. Gene-environment interactions in mental disorders. *World Psychiatr.* 2004;3(2):73–83.
- 41 Schaafsma SM, Gagnidze K, Reyes A, et al. Sex-specific gene-environment interactions underlying ASD-like behaviours. *Proc Natl Acad Sci USA.* 2017;114(6):1383–1388.
- 42 Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature.* 2018;555(7695):210–215.
- 43 Chu H, Khosravi A, Kusumawardhani IP, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. *Science.* 2016;352(6289):1116–1120.
- 44 Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. *J Med Microbiol.* 2005;54(Pt 10):987–991.
- 45 Kurokawa S, Nomura K, Miyaho K, et al. Gastrointestinal symptoms and sensory abnormalities associated with behavioural problems in children with neurodevelopmental disorders. *Autism Res.* 2021;14(9):1996–2001.
- 46 Sharon G, Cruz NJ, Kang DW, et al. Human gut microbiota from autism spectrum disorder promote behavioural symptoms in mice. *Cell.* 2019;177(6):1600–1618 e17.
- 47 Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. *Sci Rep.* 2019;9(1):5821.
- 48 Buffington SA, Dooling SW, Sgritta M, et al. Dissecting the contribution of host genetics and the microbiome in complex behaviours. *Cell.* 2021;184(7):1740–1756.e16.
- 49 Li Y, Luo ZY, Hu YY, et al. The gut microbiota regulates autism-like behaviour by mediating vitamin B6 homeostasis in EphB6-deficient mice. *Microbiome.* 2020;8(1):120.
- 50 Zhang W, Chen H, Ding L, et al. Trojan horse delivery of 4,4'-Dimethoxychalcone for parkinsonian neuroprotection. *Adv Sci.* 2021;8(9):2004555.
- 51 Golden SA, Covington 3rd HE, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. *Nat Protoc.* 2011;6(8):1183–1191.
- 52 Lugo JN, Swann JW, Anderson AE. Early-life seizures result in deficits in social behaviour and learning. *Exp Neurol.* 2014;256:74–80.
- 53 Yang M, Silverman JL, Crawley JN. Automated three-chambered social approach task for mice. *Curr Protocol Neurosci.* 2011. <https://doi.org/10.1002/0471142301.ns0826s56> [Chapter 8]: Unit 8 26.
- 54 Liu Y, Du T, Zhang W, et al. Modified Huang-Lian-Jie-Du Decoction ameliorates Abeta synaptotoxicity in a murine model of Alzheimer's disease. *Oxid Med Cell Longev.* 2019;2019:8340192.
- 55 Liu Y, Zong X, Huang J, et al. Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice. *Aging.* 2019;11(14):5008–5034.
- 56 Guan YF, Huang GB, Xu MD, et al. Anti-depression effects of ketogenic diet are mediated via the restoration of microglial activation and neuronal excitability in the lateral habenula. *Brain Behav Immun.* 2020;88:748–762.
- 57 Sgritta M, Dooling SW, Buffington SA, et al. Mechanisms underlying microbial-mediated changes in social behaviour in mouse models of autism spectrum disorder. *Neuron.* 2019;101(2):246–259 e6.
- 58 Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics.* 2011;27(21):2957–2963.
- 59 Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods.* 2010;7(5):335–336.
- 60 Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol.* 2007;73(16):5261–5267.
- 61 Zhang YL, Liu Y, Kang XP, et al. Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease. *Neuropharmacology.* 2018;131:223–237.
- 62 Kitamura T, Ogawa SK, Roy DS, et al. Engrams and circuits crucial for systems consolidation of a memory. *Science.* 2017;356(6333):73–78.
- 63 Klavir O, Prigge M, Sarel A, Paz R, Yizhar O. Manipulating fear associations via optogenetic modulation of amygdala inputs to prefrontal cortex. *Nat Neurosci.* 2017;20(6):836–844.
- 64 Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome.* 2017;5(1):10.
- 65 Janak PH, Tye KM. From circuits to behaviour in the amygdala. *Nature.* 2015;517(7534):284–292.
- 66 Roozendaal B, McEwen BS, Chattarji S. Stress, memory and the amygdala. *Nat Rev Neurosci.* 2009;10(6):423–433.
- 67 Zhang X, Kim J, Tonegawa S. Amygdala reward neurons form and store fear extinction memory. *Neuron.* 2020;105(6):1077–1093.e7.
- 68 Saha R, Knapp S, Chakraborty D, et al. GABAergic synapses at the axon initial segment of basolateral amygdala projection neurons modulate fear extinction. *Neuropsychopharmacology.* 2017;42(2):473–484.
- 69 Li KX, He M, Ye W, et al. TMEM16B regulates anxiety-related behaviour and GABAergic neuronal signaling in the central lateral amygdala. *Elife.* 2019;8.
- 70 Fujihara K, Miwa H, Kakizaki T, et al. Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes. *Neuropsychopharmacology.* 2015;40(10):2475–2486.
- 71 Chattopadhyaya B, Di Cristo G, Wu CZ, et al. GAD67-mediated GABA synthesis and signaling regulate inhibitory synaptic innervation in the visual cortex. *Neuron.* 2007;54(6):889–903.
- 72 McDonald AJ. Glutamate and aspartate immunoreactive neurons of the rat basolateral amygdala: colocalization of excitatory amino acids and projections to the limbic circuit. *J Comp Neurol.* 1996;365(3):367–379.
- 73 Baron-Cohen S, Knickmeyer RC, Belmonte MK. Sex differences in the brain: implications for explaining autism. *Science.* 2005;310(5749):819–823.
- 74 Rai AL, Jeswar U. Immunohistochemical colocalization of estrogen receptor-alpha and GABA in adult female rat hippocampus. *Ann Neurosci.* 2012;19(3):112–115.
- 75 Almey A, Milner TA, Brake WG. Estrogen receptor alpha and G-protein coupled estrogen receptor 1 are localized to GABAergic neurons in the dorsal striatum. *Neurosci Lett.* 2016;622:118–123.
- 76 Herbison AE. Estrogen regulation of GABA transmission in rat preoptic area. *Brain Res Bull.* 1997;44(4):321–326.
- 77 Noriega NC, Eghlidi DH, Garyfallou VT, Kohama SG, Kryger SG, Urbanski HF. Influence of 17beta-estradiol and progesterone on GABAergic gene expression in the arcuate nucleus, amygdala and hippocampus of the rhesus macaque. *Brain Res.* 2010;1307:28–42.
- 78 Herbison AE, Augood SJ, Simonian SX, Chapman C. Regulation of GABA transporter activity and mRNA expression by estrogen in rat preoptic area. *J Neurosci.* 1995;15(12):8302–8309.

- 79 Mukherjee J, Cardarelli RA, Cantaut-Belarif Y, et al. Estradiol modulates the efficacy of synaptic inhibition by decreasing the dwell time of GABAA receptors at inhibitory synapses. *Proc Natl Acad Sci USA*. 2017;114(44):11763–11768.
- 80 Tronson NC, Keiser AA. A dynamic memory systems framework for sex differences in fear memory. *Trends Neurosci*. 2019;42(10):680–692.
- 81 Morais LH, Schreiber HL, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. *Nat Rev Microbiol*. 2021;19(4):241–255.
- 82 Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell*. 2016;165(7):1762–1775.
- 83 Kong XJ, Liu J, Li J, et al. Probiotics and oxytocin nasal spray as neuro-social-behavioural interventions for patients with autism spectrum disorders: a pilot randomized controlled trial protocol. *Pilot Feasibility Stud*. 2020;6:20.
- 84 Messaoudi S, Manai M, Kergourlay G, et al. Lactobacillus salivarius: bacteriocin and probiotic activity. *Food Microbiol*. 2013;36(2):296–304.
- 85 Zhai Q, Shen X, Cen S, et al. Screening of Lactobacillus salivarius strains from the feces of Chinese populations and the evaluation of their effects against intestinal inflammation in mice. *Food Funct*. 2020;11(1):221–235.
- 86 Holowacz S, Blondeau C, Guinobert I, Guilbot A, Hidalgo S, Bisson JF. Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin inflammation in mice. *Benef Microbes*. 2018;9(2):299–309.